$LHCG (LHC Group, Inc.)

$LHCG {{ '2016-04-13T23:33:18+0000' | timeago}} • Announcement

Lafayette, Louisiana-based $LHCG said that it has named Joshua Proffitt as EVP, CFO and Treasurer, effective April 30, 2016. Proffitt, previously EVP, Corporate Development and General Counsel, will replace current EVP, CFO and Treasurer, Dionne Viator, who will be leaving the Company to pursue other interests.

$MD {{ '2018-01-10T15:20:12+0000' | timeago}} • Announcement

$MD announced the acquisition of Tri-Valley Neonatal Medical Group, Inc., a private neonatology physician practice based in California. This was a cash transaction and it is expected to be immediately accretive to earnings. No additional terms of the transaction were disclosed.

$OFIX {{ '2018-01-09T17:10:48+0000' | timeago}} • Announcement

$OFIX announced preliminary  4Q17 net sales of approx $117MM. These preliminary results represent reported sales growth of 7.7% and constant currency sales growth of 6.1% over 4Q16. As of Dec 31, 2017, cash and cash equivalents were approx $81MM compared to $40MM as of Dec 31, 2016.

$IART {{ '2018-01-08T12:15:32+0000' | timeago}} • Announcement

$IART said it expects 4Q17 revenue to be approx $365MM, an increase of over 40% compared to 4Q16, helped by Derma Sciences and Codman Neurosurgery acquisitions. The results will be announced in late February, 2018.

$HUM {{ '2017-12-19T15:27:46+0000' | timeago}} • Announcement

$HUM signed a definitive agreement to acquire a 40% minority interest in the Kindred at Home Division of $KND for an estimated cash consideration of approximately $800MM. Humana does not anticipate a material impact to earnings in 2017 from this pending transaction.

$KND {{ '2017-12-19T13:44:51+0000' | timeago}} • Announcement

$KND's BoD approved a definitive agreement whereby it will be acquired by a consortium of three companies: TPG Capital, Welsh, Carson, Anderson & Stowe and $HUM for about $4.1Bil in cash including the assumption or repayment of net debt. The transaction is expected to close during the summer of 2018.

$ESRX {{ '2017-12-14T15:34:37+0000' | timeago}} • Announcement

$ESRX's enterprise value initiative is currently estimated to cost approx. $600-650MM and to deliver cumulative savings of nearly $1.2Bil by 2021. The company's 2018 full-year guidance includes an estimated contribution of $65-75MM in expense savings affecting the Core and consolidated businesses.

$ESRX {{ '2017-12-14T15:34:20+0000' | timeago}} • Announcement

For 2018, $ESRX expects adjusted diluted EPS to be $7.67-7.87, up 9-12% from the midpoint of the updated 2017 adjusted EPS guidance range. The company expects consolidated revenue to be $99-102Bil and Core revenue to be $80.5-83Bil. Total adjusted claims for the consolidated business is expected to be $1.34-1.39Bil.

$ESRX {{ '2017-12-14T15:34:05+0000' | timeago}} • Announcement

$ESRX expects full-year 2017 total adjusted claims for its Core business to be 1.15-1.17Bil, which is flat over Core 2016 total adjusted claims at the midpoint of the range. The company expects Core 2017 adjusted EBITDA guidance to be $4.91-4.97Bil, representing growth of 3% over Core 2016 adjusted EBITDA results at the midpoint of the range.

$ESRX {{ '2017-12-14T15:33:48+0000' | timeago}} • Announcement

$ESRX increased its consolidated 2017 adjusted EPS guidance range to $7.00-7.08, representing growth of 10% over 2016 adjusted EPS at the midpoint of the range. The company narrowed its consolidated 2017 adjusted EBITDA guidance from $7.35-7.47Bil to $7.37-7.45Bil, maintaining the midpoint of the range and up 2% over 2016.

$AGN {{ '2017-12-12T19:07:05+0000' | timeago}} • Announcement

$AGN enters into a buyout deal with $RPRX through a cash tender offer of $0.67 per share, representing a 43% premium of Repros Therapeutics’ Dec. 11th closing price ($0.47). Allergan's subsidiary will acquire Repros, which focuses on developing the drugs for male and female reproductive disorders. The deal is expected to close in 1Q18.

$PMC {{ '2017-12-07T18:06:23+0000' | timeago}} • Announcement

$PMC announced the completion of the acquisition of PharMerica by a newly formed company controlled by KKR with an affiliate of $WBA as a minority investor.

$CVS {{ '2017-12-04T21:29:13+0000' | timeago}} • Announcement

$CVS has agreed to acquire $AET for appox. $207 per share or approx. $69Bil. Including the assumption of $AET debt, the total value of the deal is $77Bil. The transaction is expected to close in the second half of 2018.

$LHCG {{ '2017-12-04T19:56:36+0000' | timeago}} • Announcement

$LHCG and Erlanger Health System have finalized a new JV to enhance home health and community-based services in Chattanooga and southeast Tennessee. The JV includes a Chattanooga facility, which will operate as Erlanger ContinuCare Home Health. $LHCG expects annualized revenue from this JV of approx. $7MM and no material effect to 2017 diluted EPS.

$ESRX {{ '2017-11-27T17:11:32+0000' | timeago}} • Announcement

$ESRX said private equity firm Avista Capital Partners has signed a definitive agreement to acquire United BioSource (UBC), a wholly-owned subsidiary of $ESRX. UBC is a provider of pharmaceutical and patient support services, with 13 locations in the US, Europe, and Canada.

$LHCG {{ '2017-11-16T14:14:41+0000' | timeago}} • Announcement

$LHCG-$AFAM merger will create a nationwide provider of in-home healthcare services. The combined company will have 781 locations in 36 states with more than 31,000 employees and revenue of $1.8Bil and adjusted EBITDA of approx. $145MM for the trailing 12-month period ended Sept. 30, 2017.

$LHCG {{ '2017-11-16T14:13:01+0000' | timeago}} • Announcement

$LHCG and $AFAM have agreed to combine in an all-stock merger of equals transaction. Almost Family shareholders will receive 0.9150 shares of LHC Group for each existing Almost Family share. Upon closing of the transaction, LHC Group shareholders will own 58.5% and Almost Family shareholders will own 41.5% of the combined company.

$CVS {{ '2017-11-08T12:39:44+0000' | timeago}} • Webcast

For 4Q17, $CVS expects a negative free cash flow, as the company plans to settle the CMS payable associated with the 2016 plan year. Based on this the company maintains its FY17 guidance and continues to expect to produce free cash of between $6-6.4Bil

$CVS {{ '2017-11-08T12:33:21+0000' | timeago}} • Webcast

$CVS entered into a five-year agreement with $ANTM during 3Q17. Based on this, $CVS will offer its services to support $ANTM's new pharmacy benefit management company called IngenioRx, effective January 2020. The services include claims processing and prescription fulfillment through mail order and specialty pharmacies.

$CVS {{ '2017-11-08T12:24:47+0000' | timeago}} • Webcast

During 3Q17, $CVS experienced a negative effect of the three major hurricanes that hit Southern U.S. and Puerto Rico. The hurricanes along with retail weakness is what contributed to lower earnings during the quarter. The storm triggered a financial impact of approx. $55MM, which are costs primarily to cover insurance deductibles.

$RGEN {{ '2017-11-07T15:02:00+0000' | timeago}} • Announcement

$RGEN extended a long-term supply agreement with Purolite Life Sciences for the manufacture of Protein A ligands at Repligen’s facilities in Waltham, MA and Lund, Sweden. $RGEN will supply Protein A ligands to Purolite through November 2022, with an option for renewal through 2025.

Recent Transcripts

PETS (PetMed Express, Inc.)
Monday, January 22 2018 - 1:30pm
RAD (Rite Aid Corporation)
Wednesday, January 3 2018 - 10:00pm
SGMO (Sangamo Biosciences Inc.)
Thursday, November 9 2017 - 10:00pm
RGEN (Repligen Corporation)
Thursday, November 9 2017 - 1:30pm
RMTI (Rockwell Medical, Inc.)
Wednesday, November 8 2017 - 9:30pm
PRSC (Providence Service Corp.)
Wednesday, November 8 2017 - 1:00pm
RIGL (Rigel Pharmaceuticals, Inc.)
Tuesday, November 7 2017 - 10:00pm
RTRX (Retrophin, Inc.)
Tuesday, November 7 2017 - 9:30pm
KND (Kindred Healthcare Inc.)
Tuesday, November 7 2017 - 2:00pm
LHCG (LHC Group, Inc.)
Monday, November 6 2017 - 4:00pm
CVS (CVS Health Corporation)
Monday, November 6 2017 - 1:30pm
RVNC (Revance Therapeutics, Inc.)
Thursday, November 2 2017 - 8:30pm
USPH (US Physical Therapy Inc.)
Thursday, November 2 2017 - 2:30pm
RTIX (RTI Surgical Inc.)
Thursday, November 2 2017 - 12:30pm
MD (MEDNAX, Inc.)
Wednesday, November 1 2017 - 2:00pm
OFIX (Orthofix International N.V.)
Monday, October 30 2017 - 8:30pm
CHE (Chemed Corp.)
Friday, October 27 2017 - 2:00pm
TVTY (Tivity Health, Inc.)
Thursday, October 26 2017 - 9:00pm
IART (Integra LifeSciences Holdings Corporation)
Thursday, October 26 2017 - 12:30pm
SRPT (Sarepta Therapeutics, Inc.)
Wednesday, October 25 2017 - 8:30pm

AlphaGraphics you may like